anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemistry.SUBSTANCE: group of inventions relates to a multicomponent curable liquid acrylic composition for preparing a bone cement composition or dental composition, a method of producing such a composition, a syringe or a syringe-gun for delivery thereof, as well as solid cement compositions obtained by mixing said multicomponent acrylic composition. Disclosed composition comprises a storage-stable first liquid portion, a storage-stable second liquid portion, wherein the portions are configured to form cement which hardens to solid when mixing the parts together. Composition includes an acrylic monomer component, an initiator component, acrylic polymer particles and a radiopaque filler, where the initiator component is present in an amount effective for polymerisation of the acrylic monomer component when mixed and/or activated with it. At least a portion of the X-ray contrast filler is encapsulated inside and/or adsorbed on the particles of the acrylic polymer in the first liquid portion and/or the second liquid portion. Also disclosed is a syringe or a syringe gun for delivering said curable composition in surgery or dentistry, having at least two chambers comprising said liquid first portion in its first chamber and a liquid second portion in its second chamber. Method of producing the above curable composition involves the following steps: (a) obtaining said storage-stable first liquid portion and a liquid second portion which is stable during storage; (i) where step (a) comprises a step of polymerising an acrylic monomer composition to obtain acrylic polymer particles, where the polymerisation is carried out in the presence of an X-ray contrast filler for encapsulating the X-ray contrast filler in acrylic polymer particles. Liquid carrier for particles of the acrylic polymer and the encapsulated and / or adsorbed radiopaque filler can be water. When mixing said composition, porous cement is obtained. Disclosed also is a liquid composition comprising a first plurality of acrylic particles obtained by emulsion or non-emulsion polymerisation, in which a polymerisation initiator is present in an amount sufficient for the liquid composition to solidify upon contact with the reactive monomer liquid, wherein the radiopaque filler is encapsulated and/or adsorbed in a first plurality of acrylic polymer particles.EFFECT: said composition performance provides curable liquid-liquid compositions containing X-ray contrast filler without significant negative effect on mechanical properties (flexibility, expansion, fatigue strength) of the cured composition, which is observed when adding X-ray contrast filler in form of separate powder component.43 cl, 2 tbl, 8 ex
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to cardiology, and concerns normalising the functional responsiveness of cardiovascular system in arterial hypertension. That is ensured by estimating the condition of functional responsiveness of the CVS in psychoemotional load by recording systolic, diastolic, average dynamic pressure and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after load by formula: FRI=(BPav.dyn. x HR)100 (standard units). When observing the FRI gain by 20 standard units and more, losartan is prescribed in dosage 50 mg in the morning once a day and lacidipine in dosage 2 mg in the morning once a day for at least 2 months. ^ EFFECT: complex of drug-induced therapy combined with empirically prescribed treatment length provides normalisation of functional responsiveness of the CVS in the given group of the patients due to potentiation of therapeutic effect of the used drugs. ^ 2 ex
A method of detecting cardiac arrhythmia in a patient is described. This method involves determining whether there is a mutation in the nucleotide sequence, the amino acid sequence, or both, of connexin40 obtained from a patient. The mutation may be localized within the transmembrane domain of connexin40. Furthermore, there is described a method of identifying a compound for the treatment off cardiac arrhythmia. This method involves providing a cell culture that is characterized by having impaired intracellular trafficking, impaired electrical coupling, reduced gap junction plaque formation, reduced intracellular coupling, or a combination thereof, when compared to a wild-type cell. A compound is added to the cell culture, and restoration of intracellular trafficking, electrical coupling, gap junction plaque formation, intracellular coupling, or a combination thereof, is monitored.
AIMS: Amikacin requires therapeutic drug monitoring for optimum efficacy; however, the optimal model-informed precision dosing strategy for the area under the concentration-time curve (AUC) of amikacin is uncertain. This simulation study aimed to determine the efficient blood sampling points using the Bayesian forecasting approach for early achievement of the target AUC range for amikacin in critically ill patients.
METHODS: We generated a virtual population of 3000 individuals using 2 validated population pharmacokinetic models identified using a systematic literature search. AUC for each blood sampling point was evaluated using the probability of achieving a ratio of estimated/reference AUC at steady state in the 0.8-1.2 range.
RESULTS: On day 1, the 1-point samplings for population pharmacokinetic models showed a priori probabilities of 26.3 and 45.6%, which increased to 47.3 and 94.4% at 23 and 15 h, respectively. Using 2-point sampling at the peak (3 and 4 h) and trough (24 h) on day 1, these probabilities further increased to 72.3 and 99.5%, respectively. These probabilities were comparable on days 2 and 3, regardless of 3 and 6 sampling points or estimated glomerular filtration rate. These results indicated the higher predictive accuracy of 2-point sampling than 1-point sampling on day 1 for amikacin AUC estimation. Moreover, 2-point sampling was a more reasonable approach than rich sampling.
CONCLUSIONS: This study contributes to the development of an efficient model-informed precision dosing strategy for early targeting of amikacin AUC in critically ill patients.
IMPORTANCE: Gallstone pancreatitis (GSP) is the leading cause of acute pancreatitis, accounting for approximately 50% of cases. Without appropriate and timely treatment, patients are at increased risk of disease progression and recurrence. While there is increasing consensus among guidelines for the management of mild GSP, adherence to these guidelines remains poor. In addition, there is minimal evidence to guide clinicians in the treatment of moderately severe and severe pancreatitis.
OBSERVATIONS: The management of GSP continues to evolve and is dependent on severity of acute pancreatitis and concomitant biliary diagnoses. Across the spectrum of severity, there is evidence that goal-directed, moderate fluid resuscitation decreases the risk of fluid overload and mortality compared with aggressive resuscitation. Patients with isolated, mild GSP should undergo same-admission cholecystectomy; early cholecystectomy within 48 hours of admission has been supported by several randomized clinical trials. Cholecystectomy should be delayed for patients with severe disease; for severe and moderately severe disease, the optimal timing remains unclear. Preoperative endoscopic retrograde cholangiopancreatography (ERCP) is only useful for patients with suspected cholangitis or biliary obstruction, although the concomitance of these conditions in patients with GSP is rare. Modality of evaluation of the common bile duct to rule out concomitant choledocholithiasis varies and should be tailored to level of concern based on objective measures, such as laboratory results and imaging findings. Among these modalities, intraoperative cholangiography is associated with reduced length of stay and decreased use of ERCP. However, the benefit of routine intraoperative cholangiography remains in question.
CONCLUSIONS AND RELEVANCE: Treatment of GSP is dependent on disease severity, which can be difficult to assess. A comprehensive review of clinically relevant evidence and recommendations on GSP severity grading, fluid resuscitation, timing of cholecystectomy, need for ERCP, and evaluation and management of persistent choledocholithiasis can help guide clinicians in diagnosis and management.
This is a phase 1b/2, multicenter, randomized placebo-controlled double-blind study of a single dose of intravenous (IV) bacteriophage in males and non-pregnant females, at least 18 years old, diagnosed with Cystic Fibrosis (CF). This clinical trial is designed to assess the safety and microbiological activity of bacteriophage product Walter Reed Army Institute of Research- PAM-Cystic Fibrosis1 (WRAIR-PAM-CF1), directed at Pseudomonas aeruginosa (P. aeruginosa) in clinically stable CF individuals chronically colonized with P. aeruginosa. WRAIR-PAM-CF1 is a 4 component anti-pseudomonal bacteriophage mixture containing between 4 x 10\^7 and 4 x 10\^9 Plaque Forming Units (PFU) of bacteriophage. Enrollment will occur at up to 20 clinical sites in the United States. In stage 1, two sentinel subjects will be assigned to each of the three dosing arms receiving a single dosage of the IV bacteriophage therapy (4 x 10\^7 PFU, 4 x 10\^8 PFU, and 4 x 10\^9 PFU; total of 6 sentinel subjects), followed by 30 plus or minus 7 days observation period. If no Serious Adverse Events (SAEs) (related to the study product) are identified during the 96 hours after bacteriophage administration for all Sentinel Subjects in Stage 1, the study will proceed to Stage 2. In Stage 2a, 32 subjects will be enrolled into one of 4 arms (placebo IV, 4 x 10\^7 PFU, 4 x 10\^8 PFU, and 4 x 10\^9 PFU) in a 1:1:1:1 allocation. An interim analysis will be performed after all subjects have completed follow up visit 7 on Day 30 to select the IV bacteriophage dose with the most favorable safety and microbiological activity profile. During Stage 2b, subjects will be randomized into the bacteriophage (dose selected based on Interim Analysis following Stage 2a) or placebo arm. The final sample size is expected to be up to 72 subjects total with up to 25 subjects in the placebo arm and up to 25 subjects in the Stage 2b bacteriophage dose. The primary objectives of this study are to 1) describe the safety of a single dose of IV bacteriophage therapy in clinically stable CF subjects with P. aeruginosa in expectorated sputum; 2) describe the microbiological activity of a single dose of IV bacteriophage therapy in clinically stable CF subjects with P. aeruginosa in expectorated sputum; 3) describe the benefit to risk profile of a single dose of IV bacteriophage therapy in clinically stable CF subjects with P. aeruginosa in expectorated sputum.
FIELD: medicine, dermatology, pharmacy. SUBSTANCE: granule has a round or spherical central core (diameter is 25-30 mesh), covering film made of hydrophilic polymer and an antifungal agent and a layer of polymeric thickening coating. Granule has the following preferable composition, wt.-%: core substance 20-60; hydrophilic polymer 25-50; antifungal agent 10-25, and polymer forming a thickening coating 2-5. Pharmaceutical composition has an effective amount of granules showing antifungal effect. Composition can be made as gelatin capsules containing intraconizole or saperconazole as granules. Method of granule preparing involves 3 stages: 1. Core coating (size is 25-30 mesh) by spraying antifungal agent solution and hydrophilic polymer in an organic solvent that has methylene chloride and ethanol in granulator device with fluidized layer and fitted with Wurster insert (bottom spraying). 2. Drying the obtained coated cores in vacuum drum dryer. 3. Application of thickening coating on the dried cores by polymer solution spraying that forms coating in an organic solvent. This solution has methylene chloride and ethanol. Applying process is carried out in granulator device with fluidized layer and fitted with Wurster insert. EFFECT: improved bioavailability and solubility, enhanced effectiveness of treatment, improved method of preparing. 9 cl
Liquid nutritional compositions include specific combinations of protein, carbohydrate, and fat for the nutritional support of individuals with particular needs, such as individual suffering from obesity. The compositions comprise a source of at least one omega-6 fatty acid and a source of at least one omega-3 fatty acid with a ratio of omega-6 to omega-3 of 1:5 to 1:1. In a preferred form the compositions comprise at least one hydrolysed dairy protein selected from hydrolysed whey protein and hydrolysed casein protein or mixtures thereof. Methods of administering such nutritional compositions are also provided. Further liquid nutritional compositions comprise protein in an amount of 1-12% by weight of the liquid nutritional composition, vitamin C and copper, wherein the protein comprises a mixture of whey protein and casein with a majority of the whey protein having a degree of hydrolysis greater than 20%. Methods for improving vitamin C stability in these liquid nutritional compositions are also provided.
A system for the measurement of wet friction of a bundle of hair fibres includes a friction probe, a means for securing a bundle of hair fibres, and a water bath. The friction probe includes a contact surface. The friction probe is fitted with a weight in the range of from 10 g to 500 g, inclusive. The friction probe is connected to a texture analyser. The means and the friction probe are positioned in the water bath below a fill line. The contact surface of the friction probe comprises surfactant.
Hypertrophic pachymeningitis (HP) is a rare disorder marked by thickening of the dura mater due to diverse etiologies. MPO-ANCA-positive HP represents a variant of AAV confined to the central nervous system, distinguished by the presence of serum MPO antibodies. Distinguishing HP triggered by MPO-ANCA from other causes can be challenging.In this study, we present two cases of MPO-ANCA-positive HP initially misdiagnosed as intracranial infections. Case 1 underwent surgery for chronic suppurative otitis media, with histopathological findings revealing inflammatory changes without definitive suppuration. He was presumed to have a secondary intracranial infection resulting from the surgery. However, his condition deteriorated despite two weeks of antibiotic and antiviral treatment. Case 2 presented with headache and was initially suspected of having intracranial Brucellosis given his serum Brucella positivity. Despite treatment for brucellosis, his symptoms persisted, and he developed visual and hearing impairments. Both patients were ultimately diagnosed with MPO-ANCA-positive HP, exhibiting serum MPO antibody positivity. Their symptoms showed improvement with glucocorticoid and immunosuppressive therapy.Based on these observations, we propose that MPO-ANCA-positive HP may initially present as intracranial infection. For HP patients presenting with headache, mastoiditis, otitis media, and visual loss, it is imperative to conduct ANCA antibody-related tests to enhance diagnostic precision.
Therapeutic apheresis is an important hematological and nephrological method for conditions with altered plasma composition. It is also indicated for the removal of protein-bound molecules, such as bilirubin. Several techniques can remove these compounds, such as the extracorporeal circulation molecular adsorption system (MARS), plasma exchange (PEX), and plasma adsorption and perfusion (PAP). Here we report our experience in the comparison between MARS, PEX and PAP, since current guidelines do not specify which method is the most appropriate and under which circumstances it should be used. The choice of technique cannot be based on the desired plasma bilirubin concentration, since these three techniques show similar results with a similar final outcome (exitus). In fact, PAP, PEX and MARS significantly reduce bilirubin levels, but the degree of reduction is not different among the three. Furthermore, the three techniques do not differ in the rate of cholinesterase change, while less reduction of liver transaminases was found by using PAP. MARS should be preferred in the case of renal involvement (hepatorenal syndrome with hyperbilirubinemia). PAP has the advantage of being simple and inexpensive. PEX remains an option when emergency PAP is not available, but the risk of using blood products (plasma and albumin) must be considered.
Ensuring implant stability and longevity is pivotal for patient satisfaction and quality of life. Our recent discovery, BBL, novel bone bioactive liquid, demonstrated promising properties in improving implant surfaces, alleviating pain, and expediting oral healing. In this multi-center randomized, double-blind clinical trial, investigators sought to evaluate the impact of BBL on the clinical performance of Galaxy TS implants.

Methods Investigators implanted 264 Galaxy TS implants (with or without BBL) in 33 patients across both jaws. Implant stability and osseointegration were assessed using Initial Stability Quotient (ISQ) measurements, computed tomography (CBCT) scans and pain evaluations at various intervals post-surgery. Further, implant surfaces were examined using scanning electron microscopy (SEM) and atomic force microscopy (AFM). In vitro studies evaluated the efficacy of BBL on dental pulp pluripotent stem cells (DPPSCs) osteogenesis, and inflammatory factor modulation in human macrophages.
<P>PROBLEM TO BE SOLVED: To provide a method for producing powder of Suitetsu (dried Hirudo) with which dried Hirudo is dried and powdered without impairing various physiologically active substances contained in dried Hirudo and to obtain powder of dried Hirudo prepared by the production method and a thrombolysis promotion composition containing the powder of dried Hirudo.  <P>SOLUTION: Powder of dried Hirudo is obtained by washing dried Hirudo, immersing the washed dried Hirudo in ethanol, freeze-drying and grinding dried Hirudo immersed in ethanol. Preferably antioxidation treatment using nitrogen gas is carried out before grinding the freeze-dried dried Hirudo. Preferably the freeze-dried and ground dried Hirudo is thermally sterilized. The thrombolysis promotion composition comprises the powder of dried Hirudo thus obtained as an active ingredient.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Bacterial testicular inflammation is one of the important causes of male infertility. Using plant-derived compounds to overcome the side effects of antibiotics is an alternative treatment strategy for many diseases. Schizandrin B (SchB) is a bioactive compound of herbal medicine Schisandra chinensis which has multiple pharmacological effects. However its effect and the mechanism against testicular inflammation are unknown. Here we tackled these questions using models of lipopolysaccharide (LPS)-induced mice and -Sertoli cells (SCs). Histologically, SchB ameliorated the LPS-induced damages of the seminiferous epithelium and blood-testicular barrier, and reduced the production of pro-inflammatory mediators in mouse testes. Furthermore, SchB decreased the levels of pro-inflammatory mediators and inhibited the nuclear factor kB (NF-κB) and MAPK (especially JNK) signaling pathway phosphorylation in LPS-induced mSCs. The bioinformatics analysis based on receptor prediction and the molecular docking was further conducted. We targeted androgen receptor (AR) and illustrated that AR might bind with SchB in its function. Further experiments indicate that the AR expression was upregulated by LPS stimulation, while SchB treatment reversed this phenomenon; similarly, the expression of the JNK-related proteins and apoptotic-related protein were also reversed after AR activator treatment. Together, SchB mitigates LPS-induced inflammation and apoptosis by inhibiting the AR-JNK pathway.
In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram \[mg\]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.
Type 2 diabetic subjects will be assigned to 3 months of treatment with insulin detemir administered twice daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
The invention discloses a Miao medicine for reducing blood pressure. The Miao medicine is prepared from the following seven medicinal materials in mass ratio: 15-17 of rhizoma coptidis, 10-15 of achyranthes bidentata, 15-20 of pseudo-ginseng, 15-20 of salvia miltiorrhiza, 10-15 of hemsleya macrosperma, 15-20 of bulbus fritilariae and 10-15 of loranthus parasiticus. A preparation method of the Miao medicine comprises the following steps of: washing the seven medicinal materials, drying with hot air, disinfecting with ultraviolet lights, then grinding into powder of 60 meshes, finally uniformly mixing the medicinal materials in mass ratio, and preparing into pills according to a conventional Chinese medicine pill preparation method, wherein each pill contains 1 g of the medicine components. The pills are orally taken for twice every day, and four to five pills are taken each time with hot water. According to the clinical treatment and observation for 100 hypertension patients, the pills have obvious effect on 65 persons, and are effective for 29 persons and invalid for 12 persons and have the effective rate of 88%. The Miao medicine has the advantages of being few in medicinal materials used in preparation and convenient to process, having high effective rate and being suitable for treating the hypertension patients.
Fatal and life-threatening cases of cardiotoxicity, including cardiomyopathy, have been reported in patients treated with hydroxychloroquine sulfate. Signs and symptoms of cardiac compromise have occurred during acute and chronic hydroxychloroquine sulfate treatment. In multiple cases, endomyocardial biopsy showed association of the cardiomyopathy with phospholipidosis in the absence of inflammation, infiltration, or necrosis. Drug-induced phospholipidosis may occur in other organ systems [see Warnings and Precautions (5.8,5.11)]. 

Patients may present with ventricular hypertrophy, pulmonary hypertension and conduction disorders including sick sinus syndrome. ECG findings include atrioventricular, right or left bundle branch block.

Hydroxychloroquine sulfate has a potential to prolong the QT interval. Ventricular arrhythmias (including torsades de pointes) have been reported in hydroxychloroquine sulfate-treated patients. The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded [see Adverse Reactions (6), Overdosage (10)]. Avoid hydroxychloroquine sulfate administration in patients with congenital or documented acquired QT prolongation and/or known risk factors for prolongation of the QT interval such as:

  * Cardiac disease, e.g., heart failure, myocardial infarction.
  * Proarrhythmic conditions, e.g., bradycardia (< 50 bpm).
  * History of ventricular dysrhythmias.
  * Uncorrected hypokalemia and/or hypomagnesemia.
  * Concomitant administration with QT interval prolonging agents as this may lead to an increased risk for ventricular arrhythmias[see Drug Interactions (7.1)].



Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval. Correct electrolyte imbalances prior to use. Monitor cardiac function as clinically indicated during hydroxychloroquine sulfate therapy. Discontinue hydroxychloroquine sulfate if cardiotoxicity is suspected or demonstrated by tissue biopsy.